Comments
Glenmark Pharmaceuticals on Friday announced that it had been granted final approval by the United States Food & Drug Administration (USFDA) for Fingolimod capsules, 0.5 mg, the generic version of Gilenya1 capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation.
According to IQVIATM sales data for the 12 months ending April 2020, the Gilenya capsules, 0.5 mg market achieved annual sales of approximately $2.1 billion.
Shares of the company trade over 2 per cent higher at Rs 417.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.